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A splicing mutation in the aS(IV) collagen gene of a family with
Alport's syndrome. DNA sequence analysis of the a5(IV) collagen chain
gene (COL4A5) was carried out between exon 47 and 51, which encode
the noncollagenous (NC) domain, in eight Japanese families with
Alport's syndrome. In oae family with X-Iinked inheritance of the
disease, a point mutation (G to C) was found at the 3' end of exon 49 in
the COL4A5. This mutation converted the codon of a conserved
methionine-1601 to the codon for isoleucine, and also altered the normal
splicing process. The polymerase chain reaction (PCR) product ampli-
fied between exons 47 and 51 of cDNA in the affected male (hemizy-
gote) of this family contained four fragments with various molecular
weights, whereas that of a normal control contained one with the
expected molecular weight. Sequence analysis of the PCR fragments of
the male patient revealed various types of alternative splicing between
the exons, reflecting the various sizes of PCR fragments. The PCR
amplified product of the cDNA of the affected female (heterozygote), on
the other hand, contained a fragment with the same molecular weight as
the normal control. Sequence analysis of the PCR fragments of her
cDNA revealed normal splicing and no point mutation at the 3' end of
exon 49. These findings indicate that this point mutation at the consen-
sus sequence not only converted the codon but also altered the splicing
between these exons encoding the NC domain of the COL4A5. Result-
ing in missense of the aS(IV) chain, changing a large portion of the
carboxyl terminal crosslinking NC domain, this mutation can alter the
normal structure of the type IV collagen network. The absence of
abnormal PCR fragments in the cDNA study of the heterozygote may
be due to lyonization.
X-chromosome-linked Alport's syndrome is an inherited pro-
gressive renal disease often accompanied by deafness and eye
lesions [1]. The defective gene has been mapped to the Xq22-24
region using restriction fragment length polymorphism (RFLP)
markers [2, 3]. Ultrastructural studies have shown the disease
to be characterized by abnormalities of the glomerular base-
ment membrane (GBM) [4], suggesting a defect in the major
structural component, type IV collagen [5]. Immunostaining
with antibodies against the GBM have indicated alterations or
absence of a type IV collagen chain [6—8]. Complementary
DNA clones identified for the novel type IV collagen aS chain,
COL4A5, localized the gene Xq22 [9], thus suggesting it to be
the gene affected in X-linked Alport's syndrome. The COL4AS
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gene has been shown to contain a total of 51 exons now
numbered from the 5' end of the gene [10].
Subsequently, mutations have been found in the COL4A5
gene in two Utah kindreds with Alport's syndrome [11, 12].
Utah kindred EP had a deletion of about 15 kb from the 3' half
of the gene, resulting in a loss of six exons. This mutation is
likely to generate a short nonfunctional aS(IV) chain whose
presence can interfere with normal triple-helix formation. In
Utah kindred P, a single base mutation in exon 49 in DNA from
the affected individual causing a change in the codon for
cysteine to that of serine, is thought to change the right
conformation of the NC domain, which is important for both
triple-helix formation and the formation of intermolecular
cross-links of the type IV collagen molecule [11, 12]. Recently,
several other mutations have been reported in the COL4AS
gene [10, 13—18].
In this study we analyzed the DNA sequence between exons
47 and 51 of the COL4AS gene, which encodes the NC domain
of the collagen protein. One mutation was found in this region
among eight Japanese patients with Alport's syndrome and
their families. The mutation is a single base substitution (G to C)
at the 3' end of exon 49 of the COL4AS gene. This single exonic
nucleotide substitution in the consensus sequence not only
converted a conserved 1601 methionine residue in the NC
domain to isoleucine, but also caused various patterns of
splicing alterations between exon 47 and 51. We believe this
first splicing mutation to be reported on the a5(IV) collagen
chain is the cause of Alport's syndrome in this family.
Methods
Patients
Eight unassociated patients with Alport's syndrome and their
families who were followed up in our clinic were recruited for
this study. For making a diagnosis, we modified the criteria
proposed by Flinter [19]. All patients had the characteristic
electron microscopic change on their renal biopsy [4], and all
the families fulfilled at least one of the three following criteria:
(1) positive family history of hematuria, with or without renal
failure; (2) diagnostic ophthalmic signs; (3) high-tone, sensori-
neural deafness. Five families had X-linked inheritance and one
patient was thought to be a sporadic case. Further investigation
of two other patients is required for an identification of the
inheritance of their disease. All are Japanese and live in
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Fig. 1. Pedigree in three generations of a family with Alport's
syndrome.
Okayama prefecture in southwestern Japan. The family in
whom a mutation was identified is described below.
The family
Figure 1 shows the pedigree of this family. To date, we have
carried out a complete examination of the clinical phenotype,
examined pathological findings, and made a DNA study of 111-2
and 111-3.
I-i was a Japanese male who died at the age of 70 due to
pneumonia. 1-2 is a Japanese female who refused to undergo
any examination for this study. 11-3, a daughter of 1-1 and 1-2,
died at 33 years of age due to chronic renal failure a few months
after delivery of 111-3. 11-5, a son of I-i and 1-2, died at 15 years
of age also of chronic renal failure. There was no information
available on the renal, aural or ophthalmic conditions of any of
these family members. It was impossible to study other mem-
bers of the family (lI-i, 2, 4 and III-!).
111-2, a 20-year-old female, was admitted to our hospital
because of heavy proteinuria. At the age of five, macroscopic
hematuria occurred and trace proteinuria was noticed. Al-
though there was no recurrence of macroscopic hematuria, the
proteinuria gradually increased. When she was hospitalized in
May 1991, there was proteinuria of 5 to 6 g daily. Other
laboratory findings were urinary red blood cells (RBC) 7 to
lO/HPF, serum total protein 6.4 g/dl, serum albumin 3.7 gldl,
and serum creatinine 0.9 mgldl. The results of an audiogram and
an ophthalmic examination were both normal. A percutaneous
renal biopsy revealed focal segmental glomerulonephritis with
marked fibrinoid deposits in most glomeruli but no foam cells in
the interstitium. Immunofluorescence disclosed mild deposits
of IgA, 1gM and C3 with a granular pattern mainly in the
glomerular capillaries. C3 deposits were also found in the
mesangium. Electron microscopic examination disclosed typi-
cal multilamination and splitting of the GBM, but this change
was limited and most of the GBM was nearly normal. The
percental distribution of GBM alteration was about 5% accord-
ing to the method of Rumpelt [20] (Fig. 2, B-l).
111-3 is an 18-year-old male who has received hemodialysis
since the age of 15. The patient was born to a sick mother with
end-stage renal disease. His birth weight was 1,820 g. A
diagnosis of cerebral palsy was made soon after birth. At the
age of four, proteinuna was noticed. At the age of six, the
nephrotic syndrome become overt and he was hospitalized. His
first morning urine contained excessive RBCs and 700 mg/dl of
protein. Serum creatinine was 0.9 mgldl, serum protein 5.2 g/dl,
albumin 3.1 g/dl, and cholesterol 352 mg/dl. An open renal
biopsy revealed marked foam cells but no specific changes in
glomeruli were observed by light microscope. An immunofluo-
rescent study was not performed. Electron microscopic exam-
ination (Fig. 2, A and B-2) disclosed marked lamellation and
splitting of the GBM with diffuse distribution (over 90%).
Audiogram and ophthalmic test findings were normal. The
nephrotic syndrome continued and finally hemodialysis was
initiated at the age of 15.
Genomic DNA sequence analysis
Genomic DNA was obtained from the peripheral white cells
[211. For DNA sequence analysis in individual patients, the
polymerase chain reaction (PCR) was applied to the amplifica-
tion of specific segments of genomic DNA. The following
oligonucleotide primers were synthesized for the intron se-
quence adjacent to the exons according to the method of Zhou
et al [22] by PCR Mate Model 391 (ABI).
Exon 51.
NI (5'-GACGGATCCGATCTGATTGTCTTATTrCT-3')
N2 (5'-AGCTCTAGAGGAAGAGATACTTGTFGATG-3')
Exons 49 and 50112].
N3 (5 '-GACTCTAGAAAGGCCATFGCACTGGTT-3')
N4 (5 '-AGCGAATFCCTGACCTGAGTCATGTAT-3')
Exon 48.
N5 (5'-CGCTCTAGACTrFACTGTTTTCTCTC-3')
N6 (5'-GCGGAATrCAGGAGAAGGAACATAAT-3')
Exon 47.
N7 (5'-TATCTGCAGAATGCCTCATTCrITFCC-3')
N8 (5'-TFCGAATFCCAGTAGGAAATTAGATAT-3')
Each primer contained a modified 5' end to produce restric-
tion sites for subsequent cloning into the sequence vector. N2,
N3 and N5 had the XbaI site. N4, N6 and N8 had the EcoRI
site. Ni and N7 had the BamHI site and PstI site, respectively.
The DNA segment was amplified by mixing 0.1 jg of genomic
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Fig. 2. 4. Electron microscopic findings of GBM of the gloinerulus of 111-2. Typical lamellation and reticulation are found. B. Comparison of the
GBM alteration in 111-2 and 111-3. (B-I) The GBM change of 111-2 is very limited in distribution. Only one lesion can be seen in this area (arrow),
while the fusion of the foot process is diffusely found. (B-2)The GBM alteration of 111-3 is diffuse and almost all tufts are involved. Magnification:
(A) x 12,000; (B-i) and (B-2) x 1520.
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DNA as the template with 25 pmol of each primer using the
polymerase chain reaction kit GeneAmp (Perkin Elmer Cetus).
The reaction was carried out in a DNA thermal cycler pro-
grammed to denature at 94°C for one minute, to anneal at 60°C
for two minutes, and to extend at 72°C for three minutes. The
amplified products were extracted and concentrated, digested
with appropriate restriction enzymes, and electrophoresed in
0.6% agarose gel (BioRad).
The expected fragments were excised and purified, and
portions were ligated with the double-stranded replicative form
(RF) of the M13 vector, which had been digested with appro-
priate restriction enzymes. Insert-containing clones were trans-
formed into competent cells JM1O9, and then were poured onto
a YT agar plate with IPTG and Xgal. After overnight incubation
at 37°C, colorless plaques were selected to prepare the single
stranded M13 with inserts. Inserted DNA of interest in the M13
clones was sequenced by the Sanger dideoxynucleotide chain
termination method [231 using the Sequence Version 2.0 DNA
Sequencing Kit (USB) with M13 "universal primer" or specific
sequencing primers designed on the basis of the known gene
sequence [221 and made in the PCR Mate Model 391 (ABI).
RNA isolation
To explore the possibility of abnormal splicing, the mRNA of
peripheral lymphocytes of the affected individuals 111-2 (het-
erozygote) and 111-3 (hemizygote), and a control individual
were obtained to apply for RT-PCR. Lymphocytes were iso-
lated from whole blood by Histopaque (Sigma) centrifugation,
and a total of 10 x 106 cells were washed, and pelleted at room
temperature in 20 mrvi Tris-HC1, pH 7.4. The pellet was vor-
texed gently in 4 ml of 4 M guanidium isothiocyanate, 50 mM
Tris-HC1, pH 7.5, 0.5 M EDTA. Then the suspension was
placed on a 7 ml cushion of 5.6 M CsCI, 0.1 M EDTA in a 12 ml
polyallomer tube. RNA was pelleted in a SW 40ti rotor (16 hr,
16°C, 32,000 rpm). The pellet was dissolved in 400 pJ of 10 mM
Tris-HC1, pH 7.5, and the RNA was precipitated (overnight at
—20°C) by 40 d sodium acetate (2 M, pH 5.5) and 1 ml of 95%
ethanol, before it was dissolved in water treated with diethylpy-
rocarbonate [24].
Reverse transcription (RT)
Ten micrograms of total RNA were heat-denatured at 85°C
for three minutes. RT was carried out in a final volume of 20 d
at 37°C for 30 minutes, with 500 M of each dNTP, 1 mM DTT,
25 units RNAsin, and 200 units of MMLV reverse transcriptase
in a PCR buffer (10 mrvi Tris-HC1, pH 8.3, 50 m KC1, 1.5 mM
MgCI2, 100 tg BSA) containing 10 pmol primer CN1 (5'-
GGCAGCAGTAGTAAAGTTGG-3'), a 20-mer complementary
to a sequence of exon 51 of the COL4A5 (Fig. 5A). The reaction
was terminated by heating to 95°C for five minutes.
PCR amplification of COL4A5 cDNA
Reverse-transcribed cDNA was amplified in a final volume of
100 1d PCR buffer with 2.5 units of Taq polymerase, 200 /kM of
each dNTP, 50 pmol primer of CN 1, and 50 pmol of primer CN2
(5'-GTACCCGTGGTTTGGATGGT-3'), a 20-mer correspond-
ing to a sequence of exon 47 of the COL4A5 (Fig. 5A). The
reaction was carried out in a DNA thermal cycler programmed
to denature at 94°C for one minute, to anneal at 60°C for two
minutes, and to extend at 72°C for three minutes. After 25
cycles, a total of I /kl of the first PCR reaction was then
transferred to 99 /kl of a PCR buffer premix as described above,
but with 50 pmol inside the primer CN3 (5'-GATGGATCCT-
GAGACACTGCATCCTAG-3') and CN4 (5'-TTATCTAGAT-
CCCCCTGGTCCAGATGG-3'), respectively. CN3 and CN4
had the BamHI and XbaI site at the 5' end, respectively, for
subsequent cloning into the sequence vector. Twenty-five ad-
ditional cycles of amplification were carried out using the same
parameters as those for the first reaction. The PCR products
were extracted with chloroform and analyzed on a 1.2%
NuSieve GTG agarose gel (FMC Bio products).
Sequence analysis of cDNA PCR products
A sequence analysis of cDNA PCR products was carried out
using the same method described above in the genomic DNA
sequence analysis.
Results
Sequence analysis of genomic DNA between exons 47 and 51
of the COL4A5 gene
Among the eight patients with Alport's syndrome, one mu-
tation was identified between exons 47 and 51 of COL4AS in the
family described above. The results demonstrated a single base
mutation in the fragment amplified from the affected brother
(111-3) and sister (111-2) of the family, which changed a G to C at
position —1 of the splice donor site of intron 49. This mutation
changed the ATG codon for 1601 methionine to the ATC codon
for isoleucine (data not shown). Sequencing of PCR-amplified
DNA from the sister (heterozygote) gave sequences of both
normal and mutant alleles.
Analysis of cDNA of COL4A5
Figure 3 shows the different patterns and sizes of the PCR
products of cDNA in both patients (111-2 and 111-3) and the
control by agarose gel electrophoresis. The product of the
amplified cDNA of the affected male patient 111-3 (Fig. 3, Lane
1) consisted of four bands with various molecular weights, but
no band of the expected size, that is, about 800 bp (Fig. SB).
These four bands are termed the first, second, third and fourth
bands in the order of their molecular weights.
The first band was approximately 350 bp larger than that of
the healthy control. The other three bands were approximately
100 bp, 300 bp, and 300 bp smaller than that of the healthy
control, respectively.
As shown in Figure 4A, sequence analysis of the first band
clearly revealed that this PCR product of the 111-3 cDNA
contained the entire intron 49, and the point mutation 0 to C
was found at the 3' end of exon 49, corresponding to the result
of our genomic DNA study. On the basis of the known gene
sequence of COL4A5 [22], intron 49 had 345 bp so that it
reflected the difference in size revealed by the agarose gel
electrophoresis. In addition, an inframe stop codon, TGA, was
found at the 13th codon from the 3' end of exon 49.
As shown in Figure 4B, sequence analysis of the second band
revealed the absence of entire exon 49 in the COL4A5 cDNA,
and a frame shift occurred from the 3' end of exon 48, resulting
in a stop codon, TGA, at the 13th codon from 3' end of exon 48.
As shown in Figure 4C, sequence analysis of the third band
revealed the lack of whole exons 48 and 49 in the COL4A5
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Fig. 3. The difference in the size of the PCR products of the cDNA of
affected male 111-2 (lane 1), affected female 111-2 (lane 2), and the
normal control (lane 3) by agarose gel electrophoresis. The amplified
products of 111-3 eDNA consist of four bands of various molecular
weights. These bands are the first, second, third and fourth band in
order of their molecular weights. The bands have approximately 1150,
700, 500, and 500 bp, respectively, while those of 111-2 and the normal
control have one fragment with the expected size, 800 bp.
cDNA, and another frame shift occurred from the 3' end of
exon 7, creating another stop codon, TAG, at the 75th codon
from the 3' end of exon 47.
In Figure 4D, sequence analysis of the fourth band revealed
the lack of whole exons 49 and 50 in COL4A5 cDNA.
On the basis of the known gene sequence of COL4A5 [22],
the sizes of the lost exon(s) of each band reflected the differ-
ences in size revealed by agarose gel electrophoresis, as well as
the first band (Figs. 3 and SB).
These findings showed that normal splicing did not occur in
these areas encoding the NC domain of aS(IV) chain, and
alteration of the splicing process, such as the trapping of an
entire adjacent intron 49, and three patterns of skipping were
revealed. The alteration in the splicing process is summarized in
Figure 5B,
On the other hand, the product of the amplified cDNA of the
affected female patient 111-2 (heterozygote) had a molecular
weight of about 800 bp, which was same as that of the normal
control (Fig. 3, lanes 2 and 3). Various other bands were not
found by the agarose gel electrophoresis. Sequence analysis of
the PCR product of cDNA of 111-2 and the healthy control
revealed the occurrence of normal splicing between exon 47 and
51, and no single base mutation of G to C at 3' end of exon 49
was found (Fig. 4A, right).
Discussion
In the present study we identified the first example of a
splicing mutation in the COL4A5 gene in Alport's syndrome.
This point mutation found in the family under study is likely to
be the cause of Alport's syndrome for the following reasons.
First, a number of mutations in COL4A5, both major gene
arrangements [11, 13, 14] and point mutations [10, 12, 15—18],
have been linked with the Alport phenotype. Second, the
presently described mutation would lead to various alterations
in splicing between exons 47 and 51, resulting in various
abnormal translation products.
Despite the lack of protein data, as diagrammed in Figure 5,
sequencing analysis of the cDNA PCR product demonstrated
the presence of stop codons in the first, second and third bands,
and the loss of two exons 49 and 50 in the fourth band. These
findings suggest that the translation products in the carboxyl
terminal NC domain are almost half in size. Therefore, the
translation products of the patient studied here are almost
certain to be nonfunctional, and consequently may be the cause
of the disease, This domain of the type IV collagen chain is
thought to be important for both triple-helix formation and the
formation of intermolecular crosslinks of type IV collagen
molecules [25].
Renal transplantation in Alport's syndrome is not uncommon
and is usually successful [26]. Graft failure is most often due to
a well-recognized acute and chronic rejection process. How-
ever, a small number of transplanted Alport's syndrome pa-
tients have been reported to develop crescentic glomerulone-
phritis associated with anti-GBM antibodies [27, 28]. Although
whether anti-GBM antibodies after renal transplantation are
only directed against the 26 kD NC domain [29] or not [30], is
now a matter of discussion, Antignac et al reported a high
incidence of major mutations, such as large deletions and a
point mutation in a splicing site, involving the 3' end of the
COL4A5 gene among Alport's syndrome patients who devel-
oped post-transplant anti-GBM glomerulonephritis [31]. These
mutations lead, at a minimum, to the absence of the NC domain
of the a5(IV) chain bearing target epitopes of alloantibodies.
This suggests that such mutations could represent risk factors
for post-transplant anti-GBM glomerulonephritis [31]. In this
context, one should be vigilant of this complication should a
member of the family in this study undergo a renal transplan-
tation.
In this study, we used peripheral lymphocytes as a source of
the mRNA of COL4A5. It is noteworthy that the mRNA of this
gene can be obtained from lymphocytes when the PCR tech-
nique is applied. This should make it easy to obtain mRNA for
the cDNA study in Alport's syndrome. Knebelmann et al [17]
also took advantage of "ectopic transcription" using trans-
formed lymphoblasts to obtain COL4A5 cDNA. This method
has also been used with other genes, including the CF gene [32]
and dystrophin gene [33].
A diagnosis of Alport's syndrome seemed most likely in the
family studied here, although there were several atypical find-
ings, such as the lack of aural or eye disorders, heavy protein-
uria becoming overt in the early course of the disease, and the
deposition of immunoglobulins and complements in the glomer-
ulus. It was difficult to classify the family into one of the major
types proposed by Atkin, Gregory or Border [34]. While the
number of investigated members in the family was limited,
X-linked inheritance was suspected because of the lack of
male-to-male transmission of the disease, and because of the
difference in the severity of the disease between male and
female family members. It is noteworthy that several types of
mutation of the COL4A5 gene have been found in families with
deafness and in ones without deafness, although both types of
families showed X-linked inheritance of the disease. This evi-
dence suggests that in the understanding of the molecular
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pathology of Alport's syndrome, the classification or criteria for
diagnosis of the syndrome is a subject to be reconsidered.
It is also noteworthy that among the eight Japanese patients
with Alport's syndrome studied here, there was only one
mutation between exons 47 and 51 encoding the NC domain of
the aS(IV) chain. These findings suggest that the mutations in
the other patients are located in remaining exons or adjacent
regions of the gene. In addition, the possibility cannot be
excluded that there is another gene(s) for type IV collagen a
chain on the X chromosome,
In the affected female (heterozygote) of the family, why was
the abnormal PCR product of cDNA not found by the agarose
gel electrophoresis? Sequence analysis showed her cDNA
between exons 47 and 51 to be same as that of the normal
control. Since this study is based on the PCR technique, there
is a limitation to the quantitative assessment of COL4A5
transcription. In addition, we used peripheral lymphocytes to
obtain the eDNA of COL4A5. The mutant gene might have
been expressed more in her kidneys than in peripheral lympho-
cytes. However, these findings at least suggest non-random
X-chromosome inactivation (lyonization) [35]. Using the elec-
tron microscope Rumpelt found that in male patients with
Alport syndrome the percentage of distribution of CBM alter-
ation, such as multilamination and splitting, increased with age.
The distribution of the GBM change in female patients, on the
other hand, was milder than that of the male patients. It varied
A C TA C CT A C
(Intron 49)
Exon 49
Exon 50
Exon 49
Fig. 4. A.
-t
-
_S
S_a -u
- a
-.7
S
_
S
- S
S
_ -t
a
_ -I
a=
— a
- S
1122
Exon 51
Exon 48
Al
A
C
A
T
A
C
C
C
T
G
A
T
T
A
Nomura ci ol: A splicing mutation of C0L4A5 in Alport's syndrome
D G I A C
from 10% to 30% in six female patients aged less than 30 [20].
Therefore, the OEM alteration of the affected sister 111-2 in this
study was limited in distribution (Fig. 2). It may imply that the
lyonization could be the basis for the limited distribution of
GEM alteration in this affected female revealed by the electron
microscopic study.
Fig, 4, A. Nucleotide sequencing of the first FGR-ompl jfled hand
from the affected 1(1-3 (left) and the band of expected size, that is,
800 bp from the affected 11L2 (right). The entire intron 49 is trapped,
and the point mutation Q to C is found at the 3' end of exon 49 of
111-3. On the other hand, the point mutation is not found at the site,
and the normal splicing is occurred between axon 49 and 50 of lt-2.
B. Sequence analysis shows the absence of whole exon 49 in the
second amplified band. C and IL Sequence analysis also shows the
absence of whole exons 48 and 49 in the third band, and the absence
of whole exons 49 and 50 in the fourth hand.
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